NDA Submitted for Envarsus in Kidney Transplant Prophylaxis Monthly Prescribing Reference Veloxis announced the submission of a New Drug Application (NDA) to the FDA for Envarsus (tacrolimus; formerly LCP-Tacro) for prophylaxis of organ rejection in patients receiving allogenic kidney transplants. The NDA submission is based on the entire ... Veloxis Pharmaceuticals announces NDA submission for Envarsus in kidney ... |
